YAYuki Anraku

Yuki Anraku

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuki Anraku has a total of 233 co-authors. Here are the top co-authors by number of shared publications:

  • Shunsuke Kita

    Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan

    13 shared publications
  • Katsumi Maenaka

    Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan

    12 shared publications
  • Takao Hashiguchi

    Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan

    9 shared publications
  • Hirofumi Sawa

    Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan

    4 shared publications
  • Jiei Sasaki

    Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan

    4 shared publications
  • Kei Sato

    Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo

    4 shared publications

Latest Publications

  • Open Access

    Biosafety level‐3 cryo‐electron tomography of active severe acute respiratory syndrome coronavirus 2 virions

    by Hideo Fukuhara, Hisham M. Dokainish, Shunsuke Kita, Koshiro Tabata, Akira Takasu, Juha T. Huiskonen, Yuki Anraku, Tomo Nomai, Taiyo Someya, Toshiya Senda, et al.

    Understanding the structural properties of pathogenic viruses in their native, infectious state is critical for rational vaccine and drug development. However, conducting cryo‐electron microscopy (cryo‐EM) under biosafety level 3 (BSL‐3) containment presents significant challenges. Here, we established and validated a high‐end cryo‐EM workflow within a BSL‐3 facility, comprehensively integrating facility design, containment measures, sample handling, cryo‐transfer systems, and decontamination protocols. To demonstrate the utility and reproducibility of this workflow, we applied cryo‐electron tomography to investigate severe acute respiratory syndrome coronavirus 2 in its native, active state. Our observations confirm that unfixed viral particles display pleomorphic features comparable to those previously reported in fixed or inactivated preparations, validating that these structural characteristics represent native features rather than artifacts of chemical fixation. Furthermore, spatial redistribution of surface spikes was observed. The establishment of this robust BSL‐3 cryo‐EM workflow provides a practical blueprint for the structural characterization of emerging high‐consequence pathogens, supporting pandemic preparedness, vaccine development, and antiviral discovery.

  • Open Access

    Lipidated macrocyclic peptide S-880008 inhibits SARS-CoV-2 fusion by suppressing protomer dissociation at conserved spike sites

    by Takao Sanaki, Yoshimasa Kawaguchi, Yuki Anraku, Yoshifumi Kusumoto, Akihiko Sato, Shinsuke Toba, Keiichi Taniguchi, Atsuko Yamamoto, Yuki Maruyama, Tadashi Miyamoto, et al.

  • Open Access

    ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4 + and CD8 + T-cell responses and neutralizing antibody induction

    by Tomomi Kawakita, Toshiki Sekiya, Yayoi Kameda, Naoki Nomura, Marumi Ohno, Chimuka Handabile, Akari Yamaya, Hideo Fukuhara, Yuki Anraku, Shunsuke Kita, et al.

    ARNAX is a synthetic nucleotide-based Toll-like receptor 3 (TLR3) ligand that specifically stimulates the TLR3/TIR domain-containing adaptor molecule 1 (TICAM-1) pathway without activating inflammatory responses. ARNAX activates cellular immunity via cross-presentation; hence, its practical application has been demonstrated in cancer immunotherapy. Given the importance of cellular immunity in virus infections, ARNAX is expected to be a more effective vaccine adjuvant for virus infections than alum, an adjuvant approved for human use that mainly enhances humoral immunity. In the present study, the trimeric recombinant spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was prepared as a vaccine antigen and formulated with ARNAX. When T-cell and neutralizing antibody responses were evaluated in immunized mice, antigen formulated with ARNAX generated significantly larger numbers of antigenspecific CD4 + and CD8 + T cells, as well as higher titers of neutralizing antibodies, compared to antigen alone or antigen formulated with alum. In experiments where immunized mice were challenged with a SARS-CoV-2 mouse-adapted virus derived from the ancestral strain, immunization with antigen formulated with ARNAX reduced virus titers in the lungs at 3 days post-infection to a much greater extent than did immunization with either antigen alone or that formulated with alum. These results show that ARNAX potently enhances the levels of both cellular and humoral immunity above those seen with alum, providing significantly greater viral clearing responses. Thus, ARNAX may act as a useful adjuvant for prophylactic vaccines, particularly for viral infectious diseases. IMPORTANCE: Cellular immunity is a critical immunological defense system against virus infections. However, aluminum salts, the most widely used adjuvant for vaccines for human use, do not promote strong cellular immunity. To prepare for the next pandemic of viral origin, the development of Th1-type adjuvants with low adverse reactions that induce cellular immunity is necessary. ARNAX is a TLR3 agonist consisting of DNA-RNA hybrid nucleic acid, which is expected to be an adjuvant that induces cellular immunity. The present study using a coronavirus disease 2019 mouse model demonstrated that ARNAX potently induces cellular immunity in addition to humoral immunity with minimal induction of inflammatory cytokines. Therefore, ARNAX has the potential to be used as a potent and welltolerated adjuvant for vaccines against pandemic viruses emerging in the future.


  • Open Access

    Structural and virological identification of neutralizing antibody footprint provides insights into therapeutic antibody design against SARS-CoV-2 variants

    by Yuki Anraku, Shunsuke Kita, Taishi Onodera, Akihiko Sato, Takashi Tadokoro, Shiori Ito, Yu Adachi, Ryutaro Kotaki, Tateki Suzuki, Jiei Sasaki, et al.

    Medical treatments using potent neutralizing SARS-CoV-2 antibodies have achieved remarkable improvements in clinical symptoms, changing the situation for the severity of COVID-19 patients. We previously reported an antibody, NT-108 with potent neutralizing activity. However, the structural and functional basis for the neutralizing activity of NT-108 has not yet been understood. Here, we demonstrated the therapeutic effects of NT-108 in a hamster model and its protective effects at low doses. Furthermore, we determined the cryo-EM structure of NT-108 in complex with SARS-CoV-2 spike. The single-chain Fv construction of NT-108 improved the cryo-EM maps because of the prevention of preferred orientations induced by Fab orientation. The footprints of NT-108 illuminated how escape mutations such as E484K evade from class 2 antibody recognition without ACE2 affinity attenuation. The functional and structural basis for the potent neutralizing activity of NT-108 provides insights into the rational design of therapeutic antibodies.


  • Open Access

    Lipidated macrocyclic peptide S-880008 as a broad-spectrum SARS-CoV-2 fusion inhibitor

    by Takao Sanaki, Yoshimasa Kawaguchi, Yuki Anraku, Yoshifumi Kusumoto, Akihiko Sato, Shinsuke Toba, Keiichi Taniguchi, Atsuko Yamamoto, Yuki Maruyama, Tadashi Miyamoto, et al.

    Coronavirus disease 2019, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a threat to public health and the economy. Although several SARS-CoV-2 vaccines exist, they have failed to elicit effective neutralizing antibody responses against emerging SARS-CoV-2 variants harboring spike protein mutations. Moreover, while certain neutralizing-antibody-based therapies were effective in the early stages of the SARS-CoV-2 pandemic, their performance declined with the emergence of spike protein mutations. Thus, it is essential to develop antiviral agents that inhibit the early stages of viral infection by effectively targeting spike protein mutants. Broad-spectrum anti-SARS-CoV-2 activity relies on the targeting of conserved sites within the spike protein. Herein, we used mRNA display screening and chemical modification to generate S-880008, a lipid-modified macrocyclic peptide. S-880008 exhibited efficacy against a broad range of SARS-CoV-2 (including Omicron) variants and inhibited SARS-CoV-2 fusion rather than attachment via a novel mechanism. Cryo-electron microscopy analysis revealed that, unexpectedly, S-880008 simultaneously recognized the vulnerable sites of both the interface between the receptor-binding domain (RBD) and subdomain 1 (via the macrocyclic peptide portion) and the N-terminal domain of the adjacent protomer (via the acyl chain) to enforce a RBD 3-up conformation. The results of the structure-activity relationship experiments with S-880008 derivatives supported the notion that S-880008 binding inhibited fusion by suppressing protomer dissociation. Crucially, the intranasal administration of S-880008 to mouse-adapted SARS-CoV-2-infected mice significantly reduced the viral titer in lung homogenates and improved survival rates in a dose-dependent manner. Our findings show that S-880008 has the potential to overcome the increasing threat posed by emerging SARS-CoV-2 variants, providing a rationale for the design of a broad range of antiviral fusion inhibitors.

  • Open Access

    Structural basis for receptor-binding domain mobility of the spike in SARS-CoV-2 BA.2.86 and JN.1

    by Hisano Yajima, Yuki Anraku, Yu Kaku, Kanako Terakado Kimura, Arnon Plianchaisuk, Kaho Okumura, Yoshiko Nakada-Nakura, Yusuke Atarashi, Takuya Hemmi, Daisuke Kuroda, et al.

    Since 2019, SARS-CoV-2 has undergone mutations, resulting in pandemic and epidemic waves. The SARS-CoV-2 spike protein, crucial for cellular entry, binds to the ACE2 receptor exclusively when its receptor-binding domain (RBD) adopts the up-conformation. However, whether ACE2 also interacts with the RBD in the down-conformation to facilitate the conformational shift to RBD-up remains unclear. Herein, we present the structures of the BA.2.86 and the JN.1 spike proteins bound to ACE2. Notably, we successfully observed the ACE2-bound down-RBD, indicating an intermediate structure before the RBD-up conformation. The wider and mobile angle of RBDs in the up-state provides space for ACE2 to interact with the down-RBD, facilitating the transition to the RBD-up state. The K356T, but not N354-linked glycan, contributes to both of infectivity and neutralizing-antibody evasion in BA.2.86. These structural insights the spike-protein dynamics would help understand the mechanisms underlying SARS-CoV-2 infection and its neutralization.


  • Open Access

    Virological characteristics of the SARS‐CoV‐2 Omicron EG.5.1 variant

    by Shuhei Tsujino, Sayaka Deguchi, Tomo Nomai, Miguel Padilla‐Blanco, Arnon Plianchaisuk, Lei Wang, Mst Monira Begum, Keiya Uriu, Keita Mizuma, Naganori Nao, et al.

    In middle to late 2023, a sublineage of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron XBB, EG.5.1 (a progeny of XBB.1.9.2), is spreading rapidly around the world. We performed multiscale investigations, including phylogenetic analysis, epidemic dynamics modeling, infection experiments using pseudoviruses, clinical isolates, and recombinant viruses in cell cultures and experimental animals, and the use of human sera and antiviral compounds, to reveal the virological features of the newly emerging EG.5.1 variant. Our phylogenetic analysis and epidemic dynamics modeling suggested that two hallmark substitutions of EG.5.1, S:F456L and ORF9b:I5T are critical to its increased viral fitness. Experimental investigations on the growth kinetics, sensitivity to clinically available antivirals, fusogenicity, and pathogenicity of EG.5.1 suggested that the virological features of EG.5.1 are comparable to those of XBB.1.5. However, cryo‐electron microscopy revealed structural differences between the spike proteins of EG.5.1 and XBB.1.5. We further assessed the impact of ORF9b:I5T on viral features, but it was almost negligible in our experimental setup. Our multiscale investigations provide knowledge for understanding the evolutionary traits of newly emerging pathogenic viruses, including EG.5.1, in the human population.


  • Open Access

    Structure Analysis of SARS-CoV-2 Spike Protein

    by Shunsuke Kita, Taiyo Someya, Tomo Nomai, Yuki Anraku, Katsumi Maenaka

    SARS-CoV-2 spike protein plays an important role in invading host cells. Spike protein is one of the targets of neutralizing antibodies, and thus is well studied for vaccine design and development of therapeutic antibodies. Here we review our research regarding the structure analysis of SARS-CoV-2 spike protein and spike-antibody complex with X-ray crystallography and cryo-EM.

  • Open Access

    A triggering structure of SARS-CoV-2 BA.2.86 spike upon ACE2 binding for receptor-binding domain up

    by Takao Hashiguchi, Hisano Yajima, Yuki Anraku, Yu Kaku, Kanako Kimura, Arnon Plianchaisuk, Kaho Okumura, Yoshiko Nakada-Nakura, Shunsuke Kita, Jiei Sasaki, et al.

    Since 2019, SARS-CoV-2 has undergone mutations, resulting in pandemic and epidemic waves. The SARS-CoV-2 spike protein, crucial for cellular entry, is believed to bind to the ACE2 receptor exclusively when its receptor-binding domain (RBD) adopts the “up” conformation. However, whether ACE2 exclusively binds to the “up” RBD or also interacts with the “down” RBD to facilitate the conformational shift to RBD-up remains unclear. Here, we present the structures of the BA.2.86 spike alone and bound to ACE2. The N354-linked glycan contributes to the neutralizing antibody evasion in BA.2.86. Notably, we successfully observed the ACE2-bound “down” RBD, indicating a trigger structure before the RBD-up conformation. The wider and mobile angle of RBDs in the “up” state provides space for ACE2 to interact with the “down” RBD, facilitating the transition to the RBD-up state. These structural insights into the spike-protein dynamics would help understand the mechanisms underlying SARS-CoV-2 infection and its neutralization.

  • Top Cited Papers
    Open Access

    Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant

    by Tomokazu Tamura, Takashi Irie, Sayaka Deguchi, Hisano Yajima, Masumi Tsuda, Hesham Nasser, Keita Mizuma, Arnon Plianchaisuk, Saori Suzuki, Keiya Uriu, et al.

    Circulation of SARS-CoV-2 Omicron XBB has resulted in the emergence of XBB.1.5, a new Variant of Interest. Our phylogenetic analysis suggests that XBB.1.5 evolved from XBB.1 by acquiring the S486P spike (S) mutation, subsequent to the acquisition of a nonsense mutation in ORF8. Neutralization assays showed similar abilities of immune escape between XBB.1.5 and XBB.1. We determine the structural basis for the interaction between human ACE2 and the S protein of XBB.1.5, showing similar overall structures between the S proteins of XBB.1 and XBB.1.5. We provide the intrinsic pathogenicity of XBB.1 and XBB.1.5 in hamsters. Importantly, we find that the ORF8 nonsense mutation of XBB.1.5 resulted in impairment of MHC suppression. In vivo experiments using recombinant viruses reveal that the XBB.1.5 mutations are involved with reduced virulence of XBB.1.5. Together, our study identifies the two viral functions defined the difference between XBB.1 and XBB.1.5.